The General Hospital Corporation

Massachusetts Institute of Technology

Uti Limited Partnership

Anna V Moore

Zdravka Medarova

Chongzhao Ran

Mehmet Veysel Yigit

Stephen J Lippard

Pedro Santamaria

Jian Yang

Xiao-an Zhang

Xueli Zhang

Anna-Liisa Brownell

Provided herein are curcumin analogues that are able to interact with amyloid beta (A&#x3b2;) and to attenuate the copper-induced crosslinking of A&#x3b2;. Also provided herein are methods of using the compounds as imaging agents of amyloid beta and for the treatment of diseases associated with amyloid beta. Methods of preparing unlabeled and radiolabeled compounds useful for interacting with amyloid beta and pharmaceutical compositions are also provided.

Half-curcuminoids as amyloid-beta PET imaging agents

Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject.

Therapeutic nanoparticles and methods of use thereof

The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid &#x3b2; aggregates, these probes undergo a range of changes, qualifying them as 'smart' probes. The inventors have demonstrated that probes of the invention have the capacity to monitor the progression of Alzheimer's disease in an in vivo animal model. In addition, the present invention encompasses probes useful as PET imaging agents, MRI imaging agents and multimodal imaging agents, as well as related methods of detecting and imaging amyloid &#x3b2; aggregates and plaques.

Curcumin derivatives for amyloid-&#x3b2; plaque imaging

Disclosed herein is a nanosensor of miRNA activity in a target cell, and methods of use, for detection and diagnostic applications. The nanosensor comprises a delivery particle comprising an iron oxide crystal coated with a polymer; and a sensor oligonucleotide covalently attached to the polymer. The sensor oligonucleotide comprises a seed region, comprising a nucleic acid sequence that is completely complementary to the target miRNA and comprises a cleavage site which can be engaged and cleaved by the target miRNA.

miRNA profiling compositions and methods of use

Methods and compositions for imaging Brown adipose tissue (BAT) in living mammals, e.g., humans.

Imaging brown adipose tissue with curcumin derivatives

Provided herein are curcumin analogues that are able to interact with amyloid &#x3b2; (A&#x3b2;) and to attenuate the copper-induced crosslinking of A&#x3b2;. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disease or a related disorder.

Curcumin analogs

The present invention provides methods of detecting soluble amyloid &#x3b2; using curcumin-derived near infrared (NIR) imaging probes. Upon interacting with soluble amyloid &#x3b2;, these probes undergo a range of changes, qualifying them as 'smart' probes. In addition, the invention provides methods of detecting soluble amyloid &#x3b2; by positron emission tomography (PET), magnetic resonance imaging (MRI) and multimodal imaging based on the curcumin-derived NIR imaging probes and derivatives thereof.

Methods and system for detecting soluble amyloid-&#x3b2;

This invention relates to a method for using a zinc sensor compound to detect a disease associated with the disruption of zinc homeostasis, such as prostate cancer. The zinc sensor compound comprises an optical reporter having two or more recognition units where each of the recognition units is capable of associating with at least one zinc ion.

Methods for mobile zinc measurement

A gold-coated iron oxide nanoparticle, method of making thereof, and method of using thereof is disclosed. The nanoparticle is substantially toxin free (making it clinically applicable), easily functionalized, and can serve as a contrast agent for a number of imaging techniques, including imaging a subject in at least two distinct imaging modes. Further, the nanoparticle is well-suited for therapeutic uses.

Innately multimodal nanoparticles

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

Growing community of inventors

Dracut, MA, United States of America

Anna V Moore